Zobrazeno 1 - 10
of 275
pro vyhledávání: '"Bernard, Bégaud"'
Autor:
Bernard Bégaud, Judith K. Jones
Publikováno v:
Textbook of Pharmacoepidemiology. :246-256
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fa65c65ff7cdc6c0df3747f615774e4
https://doi.org/10.1002/9781119701101.ch14
https://doi.org/10.1002/9781119701101.ch14
Publikováno v:
Therapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::415ae11991bc900dc7221fc85ff31142
https://doi.org/10.1016/j.therap.2023.01.003
https://doi.org/10.1016/j.therap.2023.01.003
Publikováno v:
Therapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce2117dd96b4653815696f03a715fab6
https://doi.org/10.1016/j.therap.2023.01.001
https://doi.org/10.1016/j.therap.2023.01.001
Autor:
Bernard Bégaud
Publikováno v:
Thérapie
Thérapie, EDP Sciences, 2021, 76 (3), pp.187-190. ⟨10.1016/j.therap.2021.04.010⟩
Thérapie, EDP Sciences, 2021, 76 (3), pp.187-190. ⟨10.1016/j.therap.2021.04.010⟩
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869ba34a46bc106a331d2134b353fe11
https://doi.org/10.1016/j.therap.2021.04.010
https://doi.org/10.1016/j.therap.2021.04.010
Autor:
Bernard Bégaud
Publikováno v:
European Journal of Neurology
European Journal of Neurology, Wiley, 2022, 29 (5), pp.1289-1290. ⟨10.1111/ene.15294⟩
European Journal of Neurology, Wiley, 2022, 29 (5), pp.1289-1290. ⟨10.1111/ene.15294⟩
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eac37165add6d115e0206603069f4c2e
https://hal.archives-ouvertes.fr/hal-03696354
https://hal.archives-ouvertes.fr/hal-03696354
Autor:
Clément Mathieu, Antoine Pariente, Bernard Bégaud, Hélène Jacqmin-Gadda, Pierre Joly, Mathilde Wanneveich
Publikováno v:
Drug Safety. 44:53-62
Despite the risks associated with their use, benzodiazepines remain used more widely than wisely. In this context, a better understanding of how their patterns of use can be associated with an increased risk of death appears essential. Indeed, the st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb3c9dd573c2e1e6e218a1828ce374e
https://doi.org/10.1007/s40264-020-00992-7
https://doi.org/10.1007/s40264-020-00992-7
Autor:
Vincent Bauchau, Gaëlle Nachbaur, Hugo Arlegui, Kaatje Bollaerts, Nicolas Praet, Bernard Bégaud, Francesco Salvo
Publikováno v:
Drug Safety
Drug Safety, Springer Verlag, 2020, 43 (11), pp.1089-1104. ⟨10.1007/s40264-020-00984-7⟩
Drug Safety, Springer Verlag, 2020, 43 (11), pp.1089-1104. ⟨10.1007/s40264-020-00984-7⟩
Introduction Understanding the balance between the benefits and risks of vaccination is essential to ensure informed and adequate public health decision making. Quantitative benefit–risk models (qBRm) represent useful tools to help decision makers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74f97f1d3271f1fd65cb81223483a8c8
http://europepmc.org/articles/PMC7575467
http://europepmc.org/articles/PMC7575467
Autor:
Vincent Servant, Arnaud Pigneux, Yohann Bohbot, Nathan Mottal, Bernard Bégaud, Noel Milpied, Aude Berroneau, Emilien Bilion, Pierre Fenaux, Ghada Miremont-Salamé, Sophie Dimicoli-Salazar, Justine Perino, Hélène Théophile, Pierre Poustis, Aude Charbonnier, Kamel Laribi, Claire Calmettes
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, Wiley, In press, 86 (5), pp.991-998. ⟨10.1111/bcp.14211⟩
Br J Clin Pharmacol
British Journal of Clinical Pharmacology, Wiley, In press, 86 (5), pp.991-998. ⟨10.1111/bcp.14211⟩
Br J Clin Pharmacol
Aims Azacitidine (AZA), a pyrimidine analogue, is validated for high-risk myelodysplastic syndrome or low-blast acute myeloid leukaemia in unfit patients for more intensive treatment. This study assessed the putative link between cardiac failure (CF)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9265840ea4d242d72fd2078599c9c8fa
https://doi.org/10.1111/bcp.14211
https://doi.org/10.1111/bcp.14211
Autor:
Paola Sanchez-Pena, Amandine Gouverneur, G. Veyrac, Bernard Bégaud, Joe-Elie Salem, Julien Bezin
Publikováno v:
Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy, Springer Verlag, 2021, ⟨10.1007/s10557-021-07242-7⟩
Cardiovascular Drugs and Therapy, Springer Verlag, 2021, ⟨10.1007/s10557-021-07242-7⟩
PURPOSE: PCSK9 might affect central nervous system development, neuronal apoptosis, and differentiation. We investigate the neurocognitive adverse events associated with the use of PCSK9 inhibitors (alirocumab and evolocumab) using pharmacovigilance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::214077d6f13540132cc9cd7d2ef14192
https://hal.archives-ouvertes.fr/hal-03363610
https://hal.archives-ouvertes.fr/hal-03363610
Publikováno v:
Pharmacoepidemiology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13af5d45ab84d52f7d3409bd0eb0516c
https://doi.org/10.1002/9781119413431.ch29
https://doi.org/10.1002/9781119413431.ch29